<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746431</url>
  </required_header>
  <id_info>
    <org_study_id>FPX-01-01</org_study_id>
    <nct_id>NCT03746431</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of [225Ac]-FPI-1434 Injection</brief_title>
  <official_title>A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fusion Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fusion Pharmaceuticals Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human phase 1, non-randomized, multi-centre, open-label clinical trial&#xD;
      designed to investigate safety, tolerability, pharmacokinetics (PK) and preliminary&#xD;
      anti-tumour activity of [111In]-FPI-1547 Injection (radioimmuno-imaging agent) and&#xD;
      [225Ac]-FPI-1434 Injection (radioimmuno-therapeutic) and to establish the maximum tolerated&#xD;
      dose (MTD) and/or the recommended phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434&#xD;
      Injection in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547. The&#xD;
      study consists of a dose escalation portion, including both single and multi-dosing cohorts,&#xD;
      of approximately five cohorts and a cold antibody sub-study portion of up to three cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation: Incidence of adverse events (AEs).</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-Dose Escalation: Incidence of dose limiting toxicities (DLTs).</measure>
    <time_frame>8 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multi-Dose Escalation: Incidence of DLTs.</measure>
    <time_frame>6 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Escalation: Incidence of clinically significant clinical laboratory abnormalities.</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Escalation: Changes in electrocardiogram (ECG) parameters (PR, QRS, QT, and QTc intervals).</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cold Antibody Sub-Study: Changes in uptake of [111In]-FPI-1547 Injection following FPI-1175 Infusion in selected regions of interest on SPECT/CT images.</measure>
    <time_frame>Within two weeks of the first [111In]-FPI-1547 Injection.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cold Antibody Sub-Study: Changes in radiation dose estimates for selected tissues, organs and whole body both for [111In]-FPI-1547 and [225Ac]-FPI-1434 Injection at various dose levels following FPI-1175 Infusion.</measure>
    <time_frame>Within two weeks of the first [111In]-FPI-1547 Injection.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold Antibody Sub-Study: Tumour uptake of [111In]-FPI-1547 Injection in selected regions of interest on SPECT/CT images.</measure>
    <time_frame>Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Radiation doses for selected organs and whole body both for [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.</measure>
    <time_frame>Within one week of the [111In]-FPI-1547 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Radiation doses for tumour lesions for [225Ac]-FPI-1434 Injection.</measure>
    <time_frame>Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Clearance for radioactivity and for the targeting antibody.</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Area under the curve (AUC) for radioactivity and for the targeting antibody.</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Cmax for radioactivity and for the targeting antibody.</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Half-life for radioactivity and for the targeting antibody.</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Prostate Cancer Working Group 3 (PCWG3) guidelines.</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Changes in the corrected QT (QTc) interval in milliseconds after [225Ac]-FPI-1434 treatment, compared to baseline.</measure>
    <time_frame>Approximately 24 hours from the time of [225Ac]-FPI-1434 Injection administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Changes in human growth hormone (hGh) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor 1 (IGF-1) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor binding protein 3 (IGFBP-3) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold Antibody Sub-Study: Incidence of AEs.</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold Antibody Sub-Study: Incidence of clinically significant clinical laboratory abnormalities.</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold Antibody Sub-Study: Changes in ECG parameters (PR, QRS, QT, and QTc intervals).</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Time to response (TTR).</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Duration of response (DoR).</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Progression free survival (PFS).</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Time to Progression (TTP).</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Disease control rate (DCR).</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Cold-Antibody Sub-Study: Overall survival (OS).</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Dose Escalation: Correlation of uptake of [111In]-FPI-1547 with observed toxicities following therapeutic administration of [225Ac]-FPI-1434 Injection.</measure>
    <time_frame>Approximately one year post final [225Ac]-FPI-1434 Injection.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dose Escalation: Correlation of uptake of [111In]-FPI-1547 with biomarker results (e.g., immunohistochemistry (ICH) staining, [18F]-FDG Positron Emission Tomography (PET)).</measure>
    <time_frame>4 weeks post final [225Ac]-FPI-1434 Injection.</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Advanced Solid Tumours</condition>
  <condition>Actinium-225</condition>
  <condition>Antineoplastic Agents</condition>
  <condition>Targeted Alpha Therapy</condition>
  <condition>Radioimmunoconjugate</condition>
  <arm_group>
    <arm_group_label>[225Ac]-FPI-1434 Single-Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>[225Ac]-FPI-1434 Multi-Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FPI-1175 Cold Antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[111In]-FPI-1547 Injection</intervention_name>
    <description>[111In]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive [111In]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.</description>
    <arm_group_label>FPI-1175 Cold Antibody</arm_group_label>
    <arm_group_label>[225Ac]-FPI-1434 Multi-Dose Escalation</arm_group_label>
    <arm_group_label>[225Ac]-FPI-1434 Single-Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[225Ac]-FPI-1434 Injection multi-dose</intervention_name>
    <description>[225Ac]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of [225]-FPI-1434 Injection. Dose is per cohort assignment.</description>
    <arm_group_label>FPI-1175 Cold Antibody</arm_group_label>
    <arm_group_label>[225Ac]-FPI-1434 Multi-Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FPI-1175 Infusion</intervention_name>
    <description>FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.</description>
    <arm_group_label>FPI-1175 Cold Antibody</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[225Ac]-FPI-1434 Injection single-dose</intervention_name>
    <description>[225Ac]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of [225]-FPI-1434 Injection. Dose is per cohort assignment.</description>
    <arm_group_label>[225Ac]-FPI-1434 Single-Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old.&#xD;
&#xD;
          2. Pathologically documented, definitively diagnosed, advanced solid tumour that is&#xD;
             refractory to all standard treatment, for which no standard treatment is available, or&#xD;
             it is contraindicated, or the patient refuses standard therapy.&#xD;
&#xD;
          3. At least 2 measurable lesions: one of which is at least ≥ 20 mm in largest diameter.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.&#xD;
&#xD;
          5. Life expectancy of ≥ 3 months as judged by the treating physician.&#xD;
&#xD;
          6. Available tumour tissue (either archival or fresh biopsy) for IGF-1R&#xD;
             immunohistochemistry. Submission of the tissue is not required prior to enrollment.&#xD;
&#xD;
          7. Adequate bone marrow reserves without the use of hematopoietic growth factors, red&#xD;
             cell or platelet transfusion as evidenced by:&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1,500/ mm^3 (≥ 1.5 x 10^9/L)&#xD;
&#xD;
               2. Platelet count ≥ 100,000/ mm^3 (≥ 100 x 10^9/L)&#xD;
&#xD;
               3. Hemoglobin ≥ 9 g/dL (≥ 90 g/L)&#xD;
&#xD;
          8. Adequate renal function as evidenced by a creatinine clearance ≥ 60 mL/min using the&#xD;
             Cockcroft-Gault Equation. Actual body weight should be used for calculating creatinine&#xD;
             clearance using the Cockcroft-Gault Equation.&#xD;
&#xD;
          9. Adequate hepatic function as evidenced by:&#xD;
&#xD;
               1. Serum total bilirubin ≤ 1.5x upper limit of normal (ULN), unless patient has&#xD;
                  Gilbert's disease&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN&#xD;
                  (≤ 5 x ULN in patients with known liver metastasis)&#xD;
&#xD;
         10. Other laboratory results, vital signs and ECG are judged by the Investigator to be&#xD;
             acceptable for enrollment into the study.&#xD;
&#xD;
         11. Females of childbearing potential must have a negative pregnancy test result during&#xD;
             screening.&#xD;
&#xD;
         12. Females of childbearing potential and all men must agree to use at least two highly&#xD;
             effective forms of contraception one of which must be a barrier method, or agree to&#xD;
             remain abstinent, for the duration of study participation and 28 days following the&#xD;
             [111In]-FPI-1547 injection, and 5 months (for males) or 8 months (for&#xD;
             females)following the final [225Ac]-FPI-1434 Injection.&#xD;
&#xD;
         13. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
         14. In the judgement of the Investigator, the patient is expected to be compliant and have&#xD;
             a high probability of completing the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received a systemic therapeutic radiopharmaceutical within 6 months prior to&#xD;
             enrollment into this study.&#xD;
&#xD;
          2. Contraindications to or inability to perform the required imaging procedures in this&#xD;
             study (e.g. inability to lay flat for the image acquisitions, etc.)&#xD;
&#xD;
          3. Uncontrolled brain metastasis, including but not limited to need for treatment with&#xD;
             steroids, surgery or radiation therapy.&#xD;
&#xD;
          4. Anticancer therapy (including investigations agents) or external beam radiation&#xD;
             therapy within 14 days of the dosing of [111In]-FPI-1547 (6 weeks for mitomycin-C).&#xD;
             Ongoing androgen deprivation therapy for prostate cancer, thyroid stimulating hormone&#xD;
             suppression for differentiated thyroid cancer, somatostatin analogues for&#xD;
             neuroendocrine tumors are NOT considered exclusion criteria.&#xD;
&#xD;
          5. Has known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years. Patients with basal cell carcinoma of the skin, squamous cell&#xD;
             carcinoma of the skin or carcinoma in situ (e.g., breast cancer, cervical cancer,&#xD;
             prostate) that have undergone potentially curative therapy are not excluded. Residual&#xD;
             Common Terminology Criteria for Adverse Events (CTCAE) ≥ Grade 2 side effects of any&#xD;
             therapy mentioned above, with the exception of residual grade 2 alopecia.&#xD;
&#xD;
          6. Prior organ transplantation, including stem cell transplantation.&#xD;
&#xD;
          7. Any prior treatment with nitrosoureas or actinomycin-D.&#xD;
&#xD;
          8. Clinical relevant proteinuria (e.g. urinary dipstick analysis for proteins is 3+ [300&#xD;
             mg/dL or 4+ [1,000 mg/dL], or daily urinary protein excretion &gt; 500 mg/dL).&#xD;
&#xD;
          9. Known or suspect allergies or contraindications to the Investigational Products or any&#xD;
             component of the investigational drug formulation.&#xD;
&#xD;
         10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, diabetes (random blood sugar during screening ≥250 mg/dL [≥ 13.9 mmol/L]),&#xD;
             or psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements.&#xD;
&#xD;
         11. Received &gt; 20 Gy prior radiation to large areas of the bone marrow (e.g. external&#xD;
             radiation therapy to whole pelvis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julie LaBagnara</last_name>
    <phone>1-201-274-5260</phone>
    <email>Labagnara@fusionpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center - Hamilton Health</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De I'Universite de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quebec University Hospital- Laval</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>225-Ac Labelled Humanized Monoclonal Antibody Against IGF-1R</keyword>
  <keyword>[225Ac]-FPI-1434</keyword>
  <keyword>IGF-IR Targeted Alpha Therapeutic</keyword>
  <keyword>IGF-IR Radioligand Therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

